Find a study
Browse recruiting studies near you — free to check, always your choice.
24 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Sickle cell disease💵 May compensate
Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
Testing higher doses of VAS-101 in people with stable sickle cell disease
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen.
- Fatty liver disease (NASH/MASH)💵 May compensate
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Testing how the liver responds to glucose in fatty liver disease, and semaglutide’s effect
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Human Models of Selective Insulin Resistance: Alpelisib, Part I
Testing how insulin works in healthy people versus people at risk for type 2 diabetes
📍 Columbia University Irving Medical Center · New York, NY · Get directions →
The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin.
- Obesity / overweight💵 May compensate
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
Testing a diabetes drug in people with fatty liver and excess weight
📍 Arizona Clinical Trials · Chandler, AZ · +22 more US sites · Get directions →
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.
- Fatty liver disease (NASH/MASH)💵 May compensate
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Testing how SGLT2 inhibitors work for fatty liver disease in obese teens
📍 Ann & Robert H Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Fibrosis Lessens After Metabolic Surgery
Testing whether metabolic surgery can reduce liver scarring in obesity
📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.
- Obesity / overweight💵 May compensate
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
Testing tirzepatide to treat obesity in people with atrial fibrillation
📍 Cleveland Clinic · Cleveland, OH · Get directions →
This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo.
- Fatty liver disease (NASH/MASH)💵 May compensate
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Testing efimosfermin in people with MASH-related compensated cirrhosis
📍 GSK Investigational Site · Chandler, AZ · +29 more US sites · Get directions →
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
- Obesity / overweightHeart / cardiovascular disease💵 May compensate
Prevention of Progression of Prediabetes, Obesity and CV Risk
Testing ways to stop prediabetes and obesity from getting worse
📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.
- Fatty liver disease (NASH/MASH)💵 May compensate
Evaluating the Pharmacokinetics and Safety of Miricorilant
Testing how a drug works in the body and its safety in adults with MASH
📍 Site# 433 · San Antonio, TX · Get directions →
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Fatty liver disease (NASH/MASH)💵 May compensate
Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD
Testing a medicine at two doses for safety and effects on fats in people with high triglycerides and
📍 OrsoBio Research Site · Guadalajara, Jalisco · Get directions →
This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.
- COPD (chronic lung disease)💵 May compensate
Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
Comparing inhaled triple versus double medicines for COPD lung airways after wood smoke exposure
📍 Insituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas" · Mexico City, Tlalpan · Get directions →
This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months.
- Obesity / overweightHigh blood pressure💵 May compensate
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Testing treatments to lower high pressure in liver veins in people with advanced liver disease and
📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.
- Obesity / overweight💵 May compensate
Diazoxide Suppression Test P&F Study
Testing how insulin helps control blood sugar in people with obesity
📍 Columbia University Irving Medical Center · New York, NY · Get directions →
The goal of this study is to learn about how the hormone insulin controls blood sugar. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level.
- Fatty liver disease (NASH/MASH)💵 May compensate
Milk Thistle Clinical Trial in Pediatric NAFLD
Testing milk thistle for children with fatty liver disease
📍 University Hospitals Cleveland Medical Center · Cleveland, OH · Get directions →
Pediatric Fatty Liver disease is a growing problem in the United States and is expected to be the leading cause of Liver Transplantation in Adults in 20 years. Following lifestyle changes such as diet restrictions and exercise may be difficult to consistently maintain.
- Obesity / overweight💵 May compensate
Graded Insulin Suppression Test P&F
Testing how insulin controls blood sugar in people with obesity
📍 Columbia University Irving Medical Center · New York, NY · Get directions →
The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level.
- Obesity / overweight💵 May compensate
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
Testing how to choose weight-loss medicines for people with bipolar disorder
📍 Mayo Clinic · Rochester, MN · Get directions →
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in patients with bipolar disorder ages 18-65. The main questions it aims to answer are: * Can the investigators compare the distribution of obesity characteristics (hungry brain, hungry gut, emotional hunger) between bipolar patients and non-bipolar participants (comparing from IRB #24-002375)?
- Fatty liver disease (NASH/MASH)💵 May compensate
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Testing resmetirom in people with MASH-related liver scarring after liver transplant
📍 University of California San Diego · La Jolla, CA · +15 more US sites · Get directions →
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Effect of Insulin Lowering on Lipogenesis
Testing whether lowering insulin for one week changes liver fat in people with obesity and MASLD
📍 Columbia University Irving Medical Center · New York, NY · Get directions →
The goal of this clinical trial is to compare a one-week course of diazoxide (2 mg/kg per dose x 14 doses) and placebo in people with obesity and insulin resistance (IR) with metabolic dysfunction-associated steatotic liver disease (MASLD). The main question it aims to answer are how mitigation of compensatory hyperinsulinemia with diazoxide affects hepatic de novo lipogenesis, a major contributor to MASLD pathophysiology.
- Type 2 diabetesFatty liver disease (NASH/MASH)💵 May compensate
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
Testing a low-dose diabetes medicine to see effects on liver changes in NASH
📍 University of Florida · Gainesville, FL · Get directions →
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
- COPD (chronic lung disease)💵 May compensate
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
Testing nebulized long-acting breathing medicines vs usual short-acting ones in hospitalized COPD
📍 University of Tennessee Medical Center · Knoxville, TN · Get directions →
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.
- Obesity / overweight💵 May compensate
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
Testing metformin for weight gain caused by antipsychotic drugs in adults with intellectual
📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →
People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease. While antipsychotics contribute to this problem, their use is necessary and appropriate in a significant subgroup of individuals with IDD.
- Obesity / overweight💵 May compensate
A Self-Guided Mobile Intervention for Adults With Binge Eating and Obesity
Testing a self-guided phone program for adults with obesity and binge eating
📍 Drexel University · Philadelphia, PA · Get directions →
The proposed study is an open label, non randomized, waitlist controlled single group feasibility study of the feasibility and usability of a digital intervention (called ChangeBite) to be used by individuals with obesity and comorbid binge eating behavior. The proposed research will include approximately 30 participants.
- Fatty liver disease (NASH/MASH)💵 May compensate
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Testing miricorilant’s effect on liver fat in people with MASH
📍 University of Missouri · Columbia, MO · Get directions →
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)